Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02, Zacks reports. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million.

Lexicon Pharmaceuticals Stock Performance

LXRX stock traded up $0.02 during midday trading on Friday, reaching $0.39. 13,534,445 shares of the company's stock traded hands, compared to its average volume of 4,048,527. The firm has a market capitalization of $96.48 million, a PE ratio of -0.52 and a beta of 1.04. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.83. The company has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $1.14. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Analysts Set New Price Targets

Several equities analysts recently commented on LXRX shares. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Leerink Partners reissued a "market perform" rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday. Piper Sandler lowered their target price on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $3.67.

Remove Ads

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lexicon Pharmaceuticals stock. Bank of America Corp DE lifted its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 136,407 shares of the biopharmaceutical company's stock after purchasing an additional 29,319 shares during the quarter. Bank of America Corp DE owned about 0.06% of Lexicon Pharmaceuticals worth $101,000 at the end of the most recent quarter. Institutional investors and hedge funds own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.